During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...

[7] Renal function was assessed in every clinic visit, on days 1, 4, 8, and 11 of a 21-day cycle, or more frequently if indicated. Response of myeloma to treatment was defined as ≥ 50% decrease ...

Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...

BeiGene (NASDAQ:BGNE – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. Several ...

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...

As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...

at 09:22 Kidneyhood.org Publishes "The Evidence-Based Guide to Kidney and Renal Diets": The First Comprehensive ... and Promising Preclinical Data with EP300/CBP Bromodomain Inhibitor OPN-6602 in ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Currently, CAR-T therapies have been shown to be effective for certain blood cancers, including lymphomas, leukaemia, and multiple myeloma but the applications ... 110 More People With Thyroid, Liver, ...

It takes 10–15 years and hundreds of millions of dollars for a pharmaceutical company to navigate the Food and Drug ...